Title:
CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR, AND PREPARATION METHOD AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2018/068766
Kind Code:
A1
Abstract:
Disclosed are an optimised chimeric antigen receptor, a gene and a recombinant expression vector thereof, an engineered CD19-targeted T cell, and an application thereof. The chimeric antigen receptor is made up of CD19ScFv, the hinge domain and the transmembrane domain of CD8, the intracellular signaling domain of CD137 and the intracellular signaling domain of CD3ζ connected in series. The T cell modified with the chimeric antigen receptor CD19ScFv-CD8-CD137-CD3ζ has a good specific killing activity against CD19 positive target cells during in vitro experiments, and has a stronger function and a higher activity than known CD19-targeted T cells acting as a control.
Inventors:
YAO YIHONG (CN)
ZHU SHIGUI (CN)
YAO XIN (CN)
LI ZHIYUAN (CN)
HE JIAPING (CN)
ZHU WEI (CN)
ZHU LIN (CN)
WANG QINGXIA (CN)
LIN NANJING (CN)
ZHANG LI (CN)
HUANG JIAQI (CN)
ZHU SHIGUI (CN)
YAO XIN (CN)
LI ZHIYUAN (CN)
HE JIAPING (CN)
ZHU WEI (CN)
ZHU LIN (CN)
WANG QINGXIA (CN)
LIN NANJING (CN)
ZHANG LI (CN)
HUANG JIAQI (CN)
Application Number:
PCT/CN2017/106135
Publication Date:
April 19, 2018
Filing Date:
October 13, 2017
Export Citation:
Assignee:
CELLULAR BIOMEDICINE GROUP SHANGHAI LTD (CN)
CELLULAR BIOMEDICINE GROUP WUXI LTD (CN)
CELLULAR BIOMEDICINE GROUP WUXI LTD (CN)
International Classes:
C07K19/00; A61K38/17; A61P35/00; C07K14/725; C12N5/10; C12N15/62; C12N15/63
Domestic Patent References:
| WO2012079000A1 | 2012-06-14 | |||
| WO2015187528A1 | 2015-12-10 |
Foreign References:
| CN105418765A | 2016-03-23 |
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: